Dr. Shah’s clinical expertise and research program are focused HFpEF, which is one of the most prevalent cardiovascular diseases and for which there are few proven treatments. In 2007, Dr. Shah started the first dedicated HFpEF program in the world at Northwestern University. The Northwestern University HFpEF program has served as a model for several other similar programs in the United States and throughout the world. Dr. Shah has been continuously funded by grants from the American Heart Association and the National Institutes of Health since 2008. He directs a laboratory that investigates the pathogenesis of heart failure; conducts multicenter clinical trials of novel therapeutics for heart failure, pulmonary hypertension, and cardiac amyloidosis; and develops novel techniques for machine learning and artificial intelligence for the classification, diagnosis, and tracking of cardiovascular diseases. His is currently the principal investigator of the Data Translation Center for the NIH HeartShare Study, which is a large scale, prospective, multi-center initiative to apply next generation phenomics to identify heart failure subtypes and treatment targets. Dr. Shah’s research, which has spans basic research in animal models, clinical physiologic studies, human clinical trials, and population-based epidemiology studies, has highlighted the heterogeneity and systemic nature of the HFpEF syndrome, and has improved the understanding of the risk factors, pathogenesis, and pathophysiology of HFpEF.